Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression
Authors:
- Nadia HindiNHNadia Hindi
- Jaime Carrillo-GarcíaJCJaime Carrillo-García
- Elena Blanco-AlcainaEBElena Blanco-Alcaina
- Marta RenshawMRMarta Renshaw
- Pablo LunaPLPablo Luna
- José DuránJosé Durán
- Natalia JiménezNJNatalia Jiménez
- Pilar SanchoPSPilar Sancho
- Rafael RamosRRRafael Ramos
- David S. MouraDMDavid S. Moura
- Javier Martín-BrotoJavier Martín-Broto
Open Access
- 3 January 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 856
Abstract
Rhabdomyosarcoma (RMS) in adults is a rare and aggressive disease, which lacks standard therapies for relapsed or advanced disease. This retrospective study aimed to describe the activity of BOMP-EPI (bleomycin, vincristine, methotrexate and cisplatin alternating with etoposide, cisplatin and ifosfamide), an alternative platinum-based regimen, in adult patients with relapsed/metastatic RMS. In the study, 10 patients with RMS with a median age at diagnosis of 20.8 years and a female/male distribution of 6/4 received a mean of 2.5 cycles of BOMP-EPI. The best RECIST response was a complete response in 1/10 (10%) patients, a partial response in 5/10 (50%), stable disease in 3/10 (30%) and progression in 1/10 (10%). With a median follow-up in the alive patients from the start of therapy of 30.5 months (15.7–258), all patients progressed with a median progression-free survival of 8.47 months (95% CI 8.1–8.8), and 7/10 patients died with a median overall survival of 24.7 months (95% CI 13.7–35.6). BOMP-EPI was an active chemotherapy regimen in adults with pediatric-type metastatic RMS, with outcomes in terms of survival that seem superior to what was expected for this poor-prognosis population. Low HMGB1 expression level was identified as a predictive factor of better response to this treatment.Keywords
Funding Information
- IVAN PEREZ (GEISBECA2018, CD20/00155)
- National Institute of Health Carlos III (GEISBECA2018, CD20/00155)
This publication has 58 references indexed in Scilit:
- Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2–IGF2BP2 PathwayCancer Research, 2013
- Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)European Journal of Cancer, 2012
- Topotecan and Cyclophosphamide in Adults with Relapsed SarcomaSarcoma, 2012
- Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcomaAutophagy, 2012
- DNA interstrand crosslink repair and cancerNature Reviews Cancer, 2011
- Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experiencePediatric Blood & Cancer, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003